- Home
- BDTX vs PYXS Comparison
BDTX vs PYXS Comparison
Compare BDTX & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDTX
- PYXS
- Stock Information
- Founded
- BDTX 2014
- PYXS 2018
- Country
- BDTX United States
- PYXS United States
- Employees
- BDTX N/A
- PYXS N/A
- Industry
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- PYXS Biotechnology: Pharmaceutical Preparations
- Sector
- BDTX Health Care
- PYXS Health Care
- Exchange
- BDTX Nasdaq
- PYXS Nasdaq
- Market Cap
- BDTX 144.9M
- PYXS 124.9M
- IPO Year
- BDTX 2020
- PYXS 2021
- Fundamental
- Price
- BDTX $2.48
- PYXS $1.63
- Analyst Decision
- BDTX Strong Buy
- PYXS Strong Buy
- Analyst Count
- BDTX 4
- PYXS 8
- Target Price
- BDTX $15.50
- PYXS $10.00
- AVG Volume (30 Days)
- BDTX 476.4K
- PYXS 2.5M
- Earning Date
- BDTX 11-05-2024
- PYXS 11-12-2024
- Dividend Yield
- BDTX N/A
- PYXS N/A
- EPS Growth
- BDTX N/A
- PYXS N/A
- EPS
- BDTX N/A
- PYXS N/A
- Revenue
- BDTX N/A
- PYXS $16,146,000.00
- Revenue This Year
- BDTX N/A
- PYXS N/A
- Revenue Next Year
- BDTX N/A
- PYXS N/A
- P/E Ratio
- BDTX N/A
- PYXS N/A
- Revenue Growth
- BDTX N/A
- PYXS N/A
- 52 Week Low
- BDTX $2.31
- PYXS $1.51
- 52 Week High
- BDTX $7.66
- PYXS $6.85
- Technical
- Relative Strength Index (RSI)
- BDTX 43.96
- PYXS 32.42
- Support Level
- BDTX $2.43
- PYXS $1.57
- Resistance Level
- BDTX $2.66
- PYXS $1.71
- Average True Range (ATR)
- BDTX 0.16
- PYXS 0.12
- MACD
- BDTX 0.05
- PYXS 0.04
- Stochastic Oscillator
- BDTX 48.81
- PYXS 28.23
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.